iBio appoints Dr. Elizabeth Stoner to board, replaces Eef Schimmelpennink

iBio, Inc.

Dr. Stoner appointed as Class II director and Compensation Committee member, effective May 7, 2026.
She brings 35+ years pharma R&D experience; currently Entrepreneur Partner at MPM BioImpact.
Eef Schimmelpennink resigned immediately; departure not due to any disagreement with the Company.
Standard non-employee director compensation: $40k annual board fee, $7.5k committee fee, option grant.
CEO cites upcoming first human clinical trial for obesity and pulmonary hypertension therapies.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Evert Schimmelpennink

Member of the Board

IBIO · iBio, Inc.

Effective: 2026-05-07
Successor: Dr. Elizabeth Stoner
Filed: May 8, 2026, 7:59 PM ET

On May 7, 2026, Evert Schimmelpennink, a member of the Board, notified the Company of his decision to resign from the Board, including from his position as a member of the Compensation Committee of the Board, effective immediately.

Appointed

Dr. Elizabeth Stoner

Class II director

IBIO · iBio, Inc.

Effective: 2026-05-07
Filed: May 8, 2026, 7:59 PM ET

On May 7, 2026, the Board of Directors (the “Board”) of iBio, Inc. (the “Company”), following the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Dr. Elizabeth Stoner, M.D., M.S., to serve as a Class II director of the Company, effective May 7, 2026

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Evert Schimmelpennink resigned as Member of the Board at iBio, Inc..

Action: resigned
Role: Member of the Board

Exact text from the filing

On May 7, 2026, Evert Schimmelpennink, a member of the Board, notified the Company of his decision to resign from the Board, including from his position as a member of the Compensation Committee of the Board, effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Dr. Elizabeth Stoner was appointed as Class II director at iBio, Inc..

Action: appointed
Role: Class II director

Exact text from the filing

On May 7, 2026, the Board of Directors (the “Board”) of iBio, Inc. (the “Company”), following the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Dr. Elizabeth Stoner, M.D., M.S., to serve as a Class II director of the Company, effective May 7, 2026

View on SEC.gov

iBio, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-057945

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.